Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Marsh & McLennan, Xevant Tie Up To Ease Employer Assistance

Published 09/23/2019, 11:21 PM
Updated 07/09/2023, 06:31 AM

Marsh & McLennan Companies, Inc.’s (NYSE:MMC) unit Mercer entered into an agreement with Xevant, a market leading company providing pharmacy benefit management (PBM) and performance optimization solutions, to offer employers a unique optimization solution. With this plan, employers will be able to gain access to real-time and feasible insights into the expense and performance of the pharmacy benefit plans.

The solution is driven by the common cost concerns of employers regarding the exorbitantly priced prescription drug plans, especially specialty drugs. 68% of employers view management of cost of specialty drugs as one of the top three health benefit strategies for the coming five years.

The unique combination of Mercer’s pharmacy consulting specialists, actuaries and financial consultants along with Xevant’s X3 real-time analytics ability is expected to provide key analytics to employers through timely insights, extensive data, etc.

Moreover, employers will be able to gain traction from and resolve their challenges by identifying hyper-inflationary medicines, managing pharmacy expenditure in a better fashion and getting in-depth view of certain cost-cutting initiatives, such as formularies, networks and utilization management programs, etc.

Mercer believes that this innovative service will help employers introduce significant changes to their pharmacy benefit offerings as well as foresee future trends.

Marsh & McLennan’s Mercer subsidiary has been consistently coming up with solutions and acquiring units to boost its capabilities. This unit also announced the launch of Mercer Mobility Management Platform (MMP), a cloud-based delivery solution, in collaboration with ServiceNow in May 2019.
Mercer belongs to the Consulting segment of the company, which contributed around 45% to the company's total revenues last year.

Shares of this Zacks Rank #3 (Hold) company have rallied 20% in a year’s time, underperforming its industry’s growth of 24.6%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Stocks to Consider

Investors interested in the insurance industry might take a look at some better-ranked stocks like eHealth, Inc. (NASDAQ:EHTH) , Brown & Brown., Inc. (NYSE:BRO) and Radian Group (NYSE:RDN) .

eHealth offers private online health insurance exchange services in the United States and China. It came up with average three-quarter positive surprise of 167.2%. The stock sports a Zacks Rank #1 (Strong Buy).

Brown & Brown deals with insurance products and services. The company has a Zacks Rank #2 (Buy) and managed to deliver positive results in all the trailing four quarters, the average being 9.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Radian Group engages in the mortgage and real estate services business in the United States. The company pulled off a positive surprise of 14.29% in the last reported quarter. It carries a Zacks Rank of 2.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Radian Group Inc. (RDN): Free Stock Analysis Report

Marsh & McLennan Companies, Inc. (MMC): Free Stock Analysis Report

Brown & Brown, Inc. (BRO): Free Stock Analysis Report

eHealth, Inc. (EHTH): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.